Shuttle Pharmaceuticals Stock Current Asset
| SHPH Stock | USD 4.42 0.04 0.91% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Shuttle Pharmaceuticals' long-term financial health and intrinsic value.
As of now, Shuttle Pharmaceuticals' Total Current Assets are increasing as compared to previous years. The Shuttle Pharmaceuticals' current Other Current Assets is estimated to increase to about 305.3 K, while Non Current Assets Total are projected to decrease to under 172.9 K. Shuttle | Current Asset | Build AI portfolio with Shuttle Stock |
Shuttle Pharmaceuticals Company Current Asset Analysis
Shuttle Pharmaceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Shuttle Current Asset Historical Pattern
Today, most investors in Shuttle Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Shuttle Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Shuttle Pharmaceuticals current asset as a starting point in their analysis.
Shuttle Pharmaceuticals Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Shuttle Net Tangible Assets
Net Tangible Assets |
|
In accordance with the recently published financial statements, Shuttle Pharmaceuticals has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Shuttle Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Shuttle Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Shuttle Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Shuttle Fundamentals
| Return On Equity | -5.51 | ||||
| Return On Asset | -1.76 | ||||
| Current Valuation | 585.29 K | ||||
| Shares Outstanding | 1.07 M | ||||
| Shares Owned By Insiders | 5.82 % | ||||
| Shares Owned By Institutions | 5.67 % | ||||
| Number Of Shares Shorted | 12.19 K | ||||
| Price To Book | 1.30 X | ||||
| EBITDA | (7.78 M) | ||||
| Net Income | (9.14 M) | ||||
| Cash And Equivalents | 50.44 K | ||||
| Total Debt | 1.17 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 0.03 X | ||||
| Book Value Per Share | 3.37 X | ||||
| Cash Flow From Operations | (7.33 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (46.34) X | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 4.69 M | ||||
| Total Asset | 2.51 M | ||||
| Retained Earnings | (34.58 B) | ||||
| Working Capital | 677.15 K | ||||
| Net Asset | 2.51 M |
About Shuttle Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shuttle Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shuttle Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shuttle Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| NOAH | Noah Holdings | |
| CIG | Companhia Energetica de | |
| BBVA | Banco Bilbao Viscaya | |
| ENIC | Enel Chile SA | |
| SBSW | Sibanye Gold Ltd |
Check out Shuttle Pharmaceuticals Piotroski F Score and Shuttle Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.